CD33 and cancer: However, the use of ADCs for cancer therapy has achieved considerable success in recent years after the introduction of four clinically approved ADCs such as Brentuximab vedotin 6,7, Trastuzumab emtansine 8–11, Inotuzumab ozogamicin 12 and Gemtuzumab ozogamicin 12,13 used for the treatment of patients with lymphoma (HL and ALL), HER2-positive, CD22-positive AML and CD33-positive ALL cancers, respectively.